Short-Term PM2.5 Exposure Raised Major Cardiovascular Event Risk in High-Risk Thai Patients
Short bursts of PM2.5 exposure were linked to higher odds of acute major cardiovascular events in a nationwide Thai cohort already carrying a heavy burden of atherosclerotic disease. The signal emerged in patients whose baseline risk was already extreme: older adults, nearly all with hypertension, and most with established cardiovascular disease, diabetes, or dyslipidaemia. In that setting, a modest rise in ambient fine particulate matter was enough to tip vulnerable vascular biology toward infarction, stroke, heart failure hospitalization, or death.
The study used a time-stratified case-crossover design within the CORE-Thailand registry and analyzed 1121 individuals who experienced first-time 4P-MACE between 2011 and 2019. Each event served as its own control, allowing comparison of air pollution exposure on the day of the event and in the preceding days against control periods for the same person. Daily PM2.5 values came from nearby air quality monitors, and conditional logistic regression estimated the odds associated with each 10 µg/m³ increment in exposure across lag windows from day 0 through day 7.
Atherosclerotic Vulnerability Met Acute Environmental Stress
The cohort was clinically saturated with vascular risk. Mean age was 69.9 years, 55.8% were male, 74.6% had pre-existing atherosclerotic cardiovascular disease, 58.4% had diabetes mellitus, 98.1% had hypertension, and 83.3% had dyslipidaemia. In a population like this, endothelial dysfunction, plaque instability, impaired autonomic reserve, and a prothrombotic milieu are already established. Fine particulate pollution adds another layer of stress: systemic inflammation rises, oxidative injury increases, vascular tone shifts, and platelet activation becomes more likely. The result is not an abstract epidemiologic association. It is a biologically plausible trigger for acute vascular decompensation.
The strongest signal appeared across both single-day and moving-average exposure windows. Single-day lagged exposure from lag 1 through lag 4 was significantly associated with increased risk, and average exposure across lag 01 to lag 07 also showed a significant relationship. For each 10 µg/m³ increase in PM2.5, the odds ratio for MACEs was 1.06 for single-day lagged exposure, with 95% confidence intervals of 1.01 to 1.11. Across average-day lagged windows, the odds ratios ranged from 1.06 to 1.08 over lags 01 to 04.
The Event Signal Was Modest, but the Bedside Meaning Is Not
The numerical effect size was not dramatic, yet in a population with pervasive vascular disease, even a small relative increase can translate into meaningful clinical burden. A narrow margin separates physiologic compensation from an acute coronary or cerebrovascular event when arteries are already narrowed, plaques are vulnerable, and microvascular reserve is limited. Short-term pollution exposure likely acts less like a primary cause than a trigger, accelerating the final pathway toward thrombosis, ischemia, or hemodynamic collapse.
This pattern fits what is known about air pollution and cardiovascular biology. Fine particles can penetrate deep into the lung, provoke systemic inflammatory signaling, and alter vascular reactivity within hours to days. In patients with established atherosclerosis, that inflammatory surge may destabilize plaque caps or intensify thrombogenicity. For patients with prior stroke or heart failure, the same exposure can strain an already fragile circulation and increase the chance of hospitalization.
Why the Time-Stratified Design Strengthens the Signal
The case-crossover design is well suited to studying short-term environmental triggers because each patient serves as their own control. By comparing exposure during event periods with exposure during control periods in the same individual, the analysis reduces confounding from stable characteristics such as sex, chronic disease burden, socioeconomic background, and long-standing medication patterns. This matters in a registry defined by high baseline cardiovascular risk, where conventional between-person comparisons can be distorted by major differences in underlying disease severity.
The registry setting also gives the results clinical weight. This was not a narrowly selected laboratory cohort or a small urban sample. The analysis came from the nationwide CORE-Thailand registry, which makes the signal relevant to a real-world population receiving routine cardiovascular care across Thailand. The geographic and clinical breadth strengthen the argument that air pollution control is not only an environmental issue but also a cardiovascular prevention strategy.
A single 10 µg/m³ increase in PM2.5 carried measurable risk across the lag periods studied.
What Clinicians and Public Health Teams Should Take From the Data
The practical implication is straightforward: patients with advanced atherosclerotic risk are not insulated from day-to-day air quality fluctuations. In fact, they may be precisely the people most likely to suffer harm from short-lived pollution spikes. Counseling about exposure avoidance may deserve a place alongside blood pressure control, lipid lowering, glucose management, and smoking cessation in the prevention conversation for high-risk cardiovascular patients.
The findings also argue for stronger environmental mitigation. Public health action aimed at reducing ambient PM2.5 may have immediate cardiovascular benefits, particularly in regions where baseline cardiometabolic risk is already high. For clinicians, the results provide another reason to treat poor air quality as a meaningful trigger when evaluating clusters of acute events, unexplained symptom worsening, or seasonal rises in hospital admissions.
Study Boundaries and Remaining Clinical Questions
The study measured exposure using nearby air quality monitors rather than individual personal monitoring, so some degree of exposure misclassification is unavoidable. Daily monitoring can capture community-level pollution, but it cannot fully reflect time spent indoors, commuting patterns, or personal filtration habits. The analysis also focused on first-time MACE events among patients already registered as high cardiovascular risk, so the findings should not be stretched to lower-risk populations without caution.
Even so, the direction of effect was consistent across lag windows and aligned with known mechanisms linking particle exposure to acute vascular injury. The study leaves one especially important question open: how much of this risk could be reduced through targeted exposure reduction in the highest-risk patients, including those with prior infarction, stroke, heart failure, or uncontrolled metabolic disease? Future work will need to connect pollution data with personal exposure patterns and intervention strategies that can blunt the cardiovascular burden of dirty air.
The trial is registered with the Thai Clinical Trials Registry under TCTR20130520001, and its results add another clinically grounded warning: in patients with heavy atherosclerotic disease, even short-term PM2.5 exposure can move the event rate in the wrong direction.